Compare J B Hunt Transport Services Inc (JBHT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Recursion Pharmaceuticals Inc — how do they compare? J B Hunt Transport Services Inc trades at $230 (market cap $20.91B), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: J B Hunt Transport Services Inc is far larger — about 9.1× Recursion Pharmaceuticals Inc's market cap, and J B Hunt Transport Services Inc pays a 0.81% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 45 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| JBHT | RXRX | |
|---|---|---|
Market Cap | $20.91B | $2.31B |
Volume | 684,242 | 40,478,768 |
Sector | Industrials | Health |
52-Week High | $298.41 | $6.79 |
52-Week Low | $137.09 | $2.84 |
Typical Hold Time | 45 Days | 22 Days |
Enterprise Value | $22.05B | $1.83B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $228.42, up 1.1% with bearish technical signals but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending. Revenue stabilized at $12B in 2025 after previous declines, while profitability improved with 5.31% net margin. Analyst consensus remains strongly bullish with $287.53 price target despite ongoing securities investigations creating headline risk.
The stock presents a divergence between bearish technical indicators and positive fundamental trajectory. Upside potential exists from earnings momentum and industry tailwinds, but risks include legal investigations and cost pressures. Wall Street's 58.7% buy rating suggests confidence in long-term value despite near-term volatility from legal overhangs and fuel cost challenges.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
